Open AccessPerspectives on Treatment of Metastatic Castration‐Resistant Prostate Cancer
Author(s) -
Merseburger Axel S.,
Bellmunt Joaquim,
Jenkins Cheryl,
Parker Chris,
Fitzpatrick John M.
Publication year - 2013
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2012-0478
Subject(s) - enzalutamide , cabazitaxel , medicine , prostate cancer , abiraterone acetate , abiraterone , docetaxel , oncology , intensive care medicine , cancer , androgen deprivation therapy , androgen receptor
The arrival of several new agents—cabazitaxel, abiraterone acetate, enzalutamide, and radium‐223—is changing the treatment options and management of patients with metastatic castration‐resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.